Reviewing Radius Health Inc. (RDUS)’s and Aptose Biosciences Inc. (NASDAQ:APTO)’s results

Radius Health Inc. (NASDAQ:RDUS) and Aptose Biosciences Inc. (NASDAQ:APTO), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Radius Health Inc. 72.48M 12.04 251.26M -5.57 0.00
Aptose Biosciences Inc. N/A 0.00 25.89M -0.81 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Radius Health Inc. and Aptose Biosciences Inc.


Table 2 provides us Radius Health Inc. and Aptose Biosciences Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Radius Health Inc. -346.66% -150.2% -65.2%
Aptose Biosciences Inc. 0.00% 0% 0%

Volatility and Risk

Radius Health Inc. is 6.00% more volatile than S&P 500 due to its 1.06 beta. Competitively, Aptose Biosciences Inc. is 91.00% more volatile than S&P 500, because of the 1.91 beta.


Radius Health Inc. has a Current Ratio of 5.5 and a Quick Ratio of 5.4. Competitively, Aptose Biosciences Inc.’s Current Ratio is 6.8 and has 6.8 Quick Ratio. Aptose Biosciences Inc.’s better ability to pay short and long-term obligations than Radius Health Inc.

Analyst Ratings

Radius Health Inc. and Aptose Biosciences Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Radius Health Inc. 0 0 2 3.00
Aptose Biosciences Inc. 0 0 2 3.00

Radius Health Inc.’s consensus target price is $54.5, while its potential upside is 184.30%. Competitively Aptose Biosciences Inc. has an average target price of $5.5, with potential upside of 184.97%. The data from earlier shows that analysts opinion suggest that Aptose Biosciences Inc. seems more appealing than Radius Health Inc.

Insider & Institutional Ownership

The shares of both Radius Health Inc. and Aptose Biosciences Inc. are owned by institutional investors at 0% and 35.1% respectively. Insiders held 0.26% of Radius Health Inc. shares. Comparatively, insiders own roughly 20.4% of Aptose Biosciences Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Radius Health Inc. -4.32% -8.54% -15.11% -41.45% -41.81% -49.8%
Aptose Biosciences Inc. -8.61% -12.18% -30.56% -51.73% 12.06% -6.7%

For the past year Radius Health Inc. was more bearish than Aptose Biosciences Inc.


Aptose Biosciences Inc. beats on 8 of the 10 factors Radius Health Inc.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.